Skip to main content
Search

Monoclonal Antibodies as Therapeutic AgentsFundamentals, Therapeutic Applications and Latest Advances

Launched October 2007 Updated September 2024 31 lectures
Prof. Herman Waldmann
University of Oxford, UK
Summary

It has long been recognised that the precision of antibody recognition offers attractive prospects for therapeutic targeting. Since the discovery of monoclonal antibodies by Milstein and Kohler in 1975, antibody therapy has been evolving as a significant player in the biopharmaceutical industry. Although promise has been high progress has been... read moreless rapid than hoped. In part this is a reflection of the state of our understanding of disease pathogenesis, the, perhaps unrealistic wish to have great drugs with minimal side effects, and the difficulties in establishing proper parameters of efficacy and benefit. In part some of these problems have been overcome, whilst others remain active areas of ongoing research.

The talks will target growth areas of therapy, and the improvements to antibodies and their application needed to achieve the desired goals.

Play All talks in this series
Expand All  /  Collapse All

Improving on "Natural" Rodent Antibodies (7 Lectures)  

Antibodies in Cancer Therapy (3 Lectures)  

Diagnostic Antibodies (1 Lecture)  

Cell Surface Glycoproteins on Cells of the Immune System (1 Lecture)  

Antibodies as Immunosuppressants (6 Lectures)  

Archived Lectures *These may not cover the latest advances in the field (13 Lectures)  

Alemtuzumab (Campath-1H) in therapy of CLL
26 min
  • Prof. Kanti Rai
  • Long Island Jewish Medical Center, USA
Archived
VEGF inhibitors for anti-angiogenic therapy
71 min
  • Prof. Kari Alitalo,
  • Dr. Bronislaw Pytowski
Archived
Human antibodies produced in mice
26 min
  • Dr. Marianne Bruggemann
  • The Babraham Institute, UK
Archived
New strategies to prevent transplant rejection: from molecules to mice to monkeys to man
52 min
  • Prof. Christian Larsen
  • Emory Transplant Center, Emory University, USA
Archived
CD20 antibodies in the targeting of B-cell malignancies and autoimmunity
55 min
  • Prof. Thomas Tedder
  • Duke University Medical Center, USA
Archived
Anti-IL-2 receptor antibodies as models for cancer therapy
45 min
  • Prof. Thomas Waldmann
  • Metabolism Branch, National Cancer Institute, National Institutes of Health, USA
Archived
Anti TNF therapy in rheumatoid arthritis
58 min
  • Prof. Marc Feldmann
  • Kennedy Institute of Rheumatology, Imperial College London, UK
Archived
Novel immunotherapeutic proteins: immunoligand
36 min
  • Prof. Terry Strom
  • Beth Israel Deaconess Medical Cente and Harvard University, USA
Archived
Diagnostic immunohistopathology
21 min
  • Prof. David Mason
  • John Radcliffe Hospital, UK
Archived
Antibodies in the control of type I diabetes
56 min
  • Prof. Lucienne Chatenoud
  • Hopital Necker-Enfants Malades, France
Archived
The challenge of targeting toxins to tumors
43 min
  • Prof. Ben Seon
  • Roswell Park Cancer Institute, USA
Archived
Antibody depletion therapy in transplantation: implications for tolerance
38 min
  • Prof. Laurence Turka
  • University of Pennsylvania, USA
Archived
Antibodies as anti-virals
36 min
  • Prof. Dennis Burton
  • The Scripps Research Institute, USA
Archived